28 lectures · 152 items
11 min
6 min
11 min
17 min
16 min
37 min
16 min
10 min
19 min
7 min
18 min
1 min
EU Screening Week - Know Your Numbers Campaign
Atlas of Cardiology - Avoidable inequalities remain in cardiovascular disease burden and care 
Towards Comprehensive Cardiovascular Health Checks accross Europe
Heart failure is common in people with atrial fibrillation detected during screening
EU NextGen project advances personalised cardiology by integrating genomic and clinical data into AI models
AI-Digital Stethoscopes Outperform Traditional Screening for Significant VHD
Stroke identified as the second leading cause of death from cardiovascular disease and a major contributor of acquired long-term disability
EU Launches Ambitious "Safe Hearts Plan": A New Roadmap in Cardiovascular Health
Tackling the Enduring Cardiovascular Impact of COVID-19: New Guidance for Primary Care
GPcardio and ACC’s NCD Academy Join Forces to Strengthen Primary Care in Cardiovascular Disease Prevention
Sex Differences and Trends in Cardiovascular Risk Management: Insights from a Long-Term Primary Care Study
Primary Prevention of Atherosclerotic Cardiovascular Disease (ASCVD) in Primary care: A Systematic Review of Guidelines
Study on Cardiovascular Risk Factors and Primary Care Utilization in Spain
The Vital Role of Primary Care in Advancing Cardiovascular Health
Gamification and financial incentives to increase physical activity among patients at elevated CV risk
Slides | Take home messages of EPCCS Guidance on 'Current management of diabetes and CV risk in primary care'five years of CPR education, dispatcher training and extra AEDs in 31 North Carolina counties did not yield more survivors with good brain function than usual practice in 29 others
Presented in LBS.04 at AHA 2026 (Sunday 8 November) and published simultaneously in NEJM. RACE-CARS is a cluster-randomised trial of 60 North Carolina counties (about 8.5 million residents), 31…
stopping statins in multimorbid adults aged 70 and over without cardiovascular disease meets the noninferiority margin but gives 38 percent more deaths, infarctions and strokes
Presented in LBS.03 at AHA 2026 (Saturday 7 November) and published simultaneously in NEJM. STREAM randomised 1,880 adults aged 70 or over (mean 77.5, 46.9 percent women, 32.1 percent diabetes, 53.5…
This Circulation review examines how a broad spectrum of anticancer therapies, including chemotherapy, hormonal agents, and targeted inhibitors, significantly increases the risk of venous and…
the oral GLP-1 agonist orforglipron is cardiovascularly non-inferior to insulin glargine in high-risk type 2 diabetes, with an unproven mortality signal and a third of the hypoglycaemia
Presented at EASD 2026 in Milan by Klara Klein and published simultaneously in The Lancet. ACHIEVE-4, an event-driven, open-label phase 3 trial at 317 sites in 16 countries, randomised 2,749 adults…
retatrutide yields up to 18.8 percent weight loss and a 10.8 mmHg lower systolic blood pressure in obesity with type 2 diabetes, with hypotension and dysesthesia as new signals
Presented at EASD 2026 in Milan and published simultaneously in The Lancet. TRIUMPH-2 randomised 1,152 adults with obesity or overweight (BMI 27 or higher, mean 38.2) and type 2 diabetes (mean HbA1c…
CagriSema lowers HbA1c by 0.16 points and weight by 4 points more than semaglutide in type 2 diabetes (REIMAGINE 2), zenagamtide follows
Amylin day at EASD 2026 in Milan. REIMAGINE 2 (Lancet Diabetes and Endocrinology) randomised 2,713 adults with type 2 diabetes on metformin with or without an SGLT2 inhibitor (mean HbA1c 8.2 percent…
retatrutide monotherapy lowers HbA1c by up to 1.1 percentage points more than placebo and body weight by up to 15 percent
Phase 3, double-blind trial in 537 adults with type 2 diabetes inadequately controlled on diet and exercise (mean HbA1c 7.9 percent, BMI 35.8, diabetes duration 2.5 years), randomised to once-weekly…
association, causality, and preventive potential.
A large prospective cohort study of nearly 500,000 UK Biobank participants, combined with bidirectional Mendelian randomization, evaluated 323 modifiable risk factors for ischemic stroke. Eighteen…
A COMBINE-AF Analysis.
A pooled analysis of five pivotal randomized trials (COMBINE-AF; n=73,737) demonstrates that extracranial bleeding occurs in 26% of patients with atrial fibrillation on oral anticoagulants over a…
1,300 ESC congress delegates measured, with excess weight in 47 percent, untreated hypertension and silent atherosclerosis in one in five
Cross-sectional health check of more than 1,300 healthcare professionals at ESC Congress 2025 with age- and sex-matched general-population controls. Excess weight 46.8 percent, hypertension 23.2…
imaging finds silent atherosclerosis in 57 percent of 16,808 adults without heart disease, and SCORE2 misses most of them
Prospective cross-sectional study in Denmark and Spain: 16,808 adults aged 18 to 70 without known cardiovascular disease, balanced by decade and sex, imaged with 3D vascular ultrasound of carotid and…
multidisciplinary, also home-based and digital, and for far more patients than the post-infarction group
Published today in the European Heart Journal ahead of its Monday presentation: the first dedicated ESC guideline on cardiac rehabilitation, chaired by Maria Bäck (Gothenburg), Matthias Wilhelm…